兽用活性药物原料製造市场－全球产业规模、份额、趋势、机会与预测：按服务类型、合成类型、动物类型、治疗类别、地区和竞争格局划分，2021-2031年

全球兽用活性药物成分市场预计将从 2025 年的 105.6 亿美元大幅成长至 2031 年的 162.7 亿美元，复合年增长率为 7.47%。

这些医药原料药是生产牲畜和伴侣动物用药品的重要药理成分。通用感染疾病率的上升以及对先进治疗方案的需求不断增长，以及全球对优质动物蛋白需求的持续增长，共同推动了这一市场的增长。此外，将宠物视为家庭成员的趋势也促使兽医保健领域获得了大量投资。根据美国宠物用品协会（APPA）预测，到2024年，美国宠物产业的总支出预计将达到约1,520亿美元，这将为上游医药原料需求的成长提供强劲的资金基础。

然而，由于不同国际司法管辖区监管标准严格且多样，市场面临许多障碍。製造商必须遵守欧洲药品管理局和美国食品药物管理局等机构执行的严格核准程序，导致合规成本增加和研发週期延长。这种监管碎片化减缓了新活性成分的商业性化进程，并对寻求拓展全球新市场的製造商构成重大障碍。

市场驱动因素

全球宠物拥有率的不断攀升以及人们对动物日益增长的拟人化观念，是推动宠物行业发展的主要动力，也促使该行业的重心从简单的疾病治疗转向更先进的健康维护和预防保健。饲主越来越将宠物视为家庭成员，因此他们更愿意为骨关节炎、皮肤病和心臟病等慢性疾病的专科治疗付费。这种文化转变要求建立可靠的、多样化的活性成分供应链，以支持长期用药方案。根据北美宠物健康保险协会2024年5月的数据，美国宠物保险保费达到39亿美元，为确保消费者能够获得高成本治疗以及维持生产需求奠定了坚实的财务基础。

除了伴侣动物领域，对动物性食品蛋白日益增长的需求也推动了畜牧业和水产养殖业提高生产效率的迫切需求。为了满足不断增长的人口粮食需求，生产者在高密度养殖条件下大量使用兽药来维持牲畜健康并预防疾病，这导致抗感染剂和驱虫药的需求增加。 2024年4月，美国农业部海外农业局预测，全球家禽产量将达到创纪录的1.033亿吨，凸显了对药品支持的巨大需求。此外，硕腾公司（Zoetis）在2024年公布的2023财年营收为85亿美元，反映出原料药生产商必须应对庞大的市场规模，以确保基本药物的持续供应。

市场挑战

兽用活性药物成分生产市场面临的一大限制因素是全球各地监管标准的差异。製造商被迫遵守欧洲药品管理局 (EMA) 和美国食品药物管理局 (FDA) 等机构制定的各种且经常相互矛盾的核准通讯协定。这种监管碎片化导致重复的安全测试和行政文件编制，显着增加了营运成本，并占用了本应用于设施扩建和製程优化的资金。

因此，新原料的商业化所需时间不断延长，导致製造商无法快速回应新兴市场的需求。这种漫长的研发过程提高了市场进入门槛，尤其对于缺乏充足资金的中小型企业而言更是如此。根据HealthforAnimals发布的2023年报告，一种新的动物用药品上市平均需要1亿美元的投资，耗时长达10年。如此漫长的研发週期延缓了活性成分生产商的产生收入势头，并减缓了产业获得新治疗方案的速度。

市场趋势

该产业正将其重心从传统的化学合成转向复杂的生物工艺，推动向生物製药和单株抗体生产的转型。製造商正加大对生物反应器和低温运输物流等专用基础设施的投资，以生产对伴侣动物具有更高特异性和更少副作用的大分子治疗药物。这项转型得益于治疗皮肤炎和骨关节炎等慢性疾病的生物製药的商业性成功。例如，2025年11月，硕腾公司宣布投资5.9亿美元在乔治亚道格拉斯维尔新建一座工厂，旨在扩大其单株抗体和疫苗的产能，凸显了这项转型所需的巨额资本投入。

同时，动物用药品公司正加速将生产外包给合约研发生产机构（CDMO），以降低现代活性原料药（API）生产相关的高昂营运成本和技术复杂性。透过利用CDMO，製药公司无需承担维护庞大内部设施的负担，即可利用先进技术和可扩展的生产能力，从而将资源集中于药物研发。这种对外部合作伙伴的依赖正在推动供应商之间的整合。例如，SeQuent Scientific于2025年11月核准与Viyash Lifesciences合併，合併后的公司半年销售额将达到164.62亿卢比，以满足其国际客户日益增长的外包需求。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：兽用活性药物原料生产全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 服务类型（内部生产、契约製造）
  • 依合成类型（化学原料药、生物原料药、高活性原料药）
  • 动物类型（生产性动物、伴侣动物）
  • 治疗类别（抗寄生虫药、抗感染药、非类固醇消炎剂、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美兽用活性药物原料生产市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲兽用活性药物原料製造市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区兽用活性药物原料製造市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲兽用活性药物原料製造市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲兽用活性药物原料生产市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球兽用活性药物原料製造市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zoetis Inc.
• Alivira Animal Health Limited
• Ofichem Group
• Chempro Group
• Siflon Group
• Qilu Animal Health Products Co., Ltd.
• Chemo Holding, SL
• SUAN FARMA SAU
• MENADIONA
• Excel Industries Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market is projected to expand significantly, growing from USD 10.56 billion in 2025 to USD 16.27 billion by 2031, representing a CAGR of 7.47%. These active pharmaceutical ingredients serve as the essential pharmacological components utilized in creating medications for both livestock and companion animals. This market growth is fundamentally underpinned by the rising incidence of zoonotic diseases, which demands sophisticated therapeutic solutions, as well as the increasing global requirement for high-quality animal protein. Furthermore, the trend of treating pets as family members has spurred substantial investment in veterinary healthcare; according to the American Pet Products Association, total U.S. pet industry spending reached nearly USD 152 billion in 2024, providing a solid financial base that fuels the demand for upstream pharmaceutical ingredients.

However, the market faces obstacles due to the complexity of meeting strict and varying regulatory standards across different international jurisdictions. Manufacturers must navigate demanding approval procedures enforced by bodies such as the European Medicines Agency and the FDA, leading to elevated compliance costs and prolonged development timelines. This regulatory fragmentation can delay the commercial introduction of new active ingredients and creates significant barriers for manufacturers aiming to extend their operations into new global markets.

Market Driver

The rising global trend of pet ownership and animal humanization serves as a major growth engine, shifting the industry's focus from simple disease treatment to advanced wellness and preventive care. Owners increasingly view their pets as integral family members, showing a greater willingness to pay for specialized therapies for chronic issues such as osteoarthritis, dermatology, and cardiology. This cultural shift necessitates reliable supply chains for diverse active ingredients to support long-term medication regimens. Data from the North American Pet Health Insurance Association in May 2024 indicated that U.S. pet insurance premiums hit USD 3.9 billion, establishing a financial trajectory that ensures consumer access to expensive treatments and sustains manufacturing demand.

Parallel to the companion animal sector, the escalating demand for animal-derived food proteins drives the need for enhanced production efficiencies in livestock and aquaculture. To feed a growing population, producers rely heavily on veterinary pharmaceuticals to maintain herd health and prevent disease in high-density farming environments, thereby increasing the volume of anti-infectives and parasiticides required. The USDA Foreign Agricultural Service forecast in April 2024 that global chicken meat production would reach a record 103.3 million tons, highlighting the massive scale requiring pharmaceutical support. Furthermore, Zoetis reported fiscal year 2023 revenue of USD 8.5 billion in 2024, reflecting the substantial market value that API manufacturers must service to ensure the continuous availability of essential medicines.

Market Challenge

A significant restraint on the veterinary active pharmaceutical ingredients manufacturing market is the difficulty of complying with divergent regulatory standards across global jurisdictions. Manufacturers are compelled to navigate distinct and often conflicting approval protocols set by agencies like the European Medicines Agency and the FDA. This regulatory fragmentation necessitates the duplication of safety studies and administrative documentation, which significantly raises operational costs and diverts capital away from facility expansion or process optimization.

Consequently, the time required to commercialize new ingredients is extended, preventing manufacturers from swiftly addressing emerging market needs. This lengthy duration creates high barriers to entry, particularly for smaller firms without deep financial reserves. According to HealthforAnimals in 2023, the process to bring a new veterinary medicine to market required an average investment of USD 100 million and spanned up to ten years. These prolonged development timelines delay the revenue generation phase for active ingredient producers, thereby hampering overall market momentum and reducing the speed at which new therapeutic options become available to the industry.

Market Trends

The industry is undergoing a shift toward biopharmaceutical and monoclonal antibody production, moving focus from traditional chemical synthesis to complex biological processes. Manufacturers are increasingly investing in specialized infrastructure, such as bioreactors and cold-chain logistics, to produce large-molecule therapeutics that offer higher specificity and fewer side effects for companion animals. This transition is driven by the commercial success of biologics for chronic conditions like dermatitis and osteoarthritis. For instance, Zoetis announced in November 2025 a USD 590 million investment in a new facility in Douglasville, Georgia, designed to expand capacity for monoclonal antibodies and vaccines, underscoring the massive capital commitment required for this evolution.

Simultaneously, there is a trend of accelerated outsourcing to Contract Development and Manufacturing Organizations (CDMOs) as animal health companies seek to mitigate the high operational costs and technical complexities associated with modern API production. By leveraging CDMOs, pharmaceutical firms can access advanced technologies and scalable production capacity without the burden of maintaining extensive internal facilities, allowing them to focus resources on drug discovery. This reliance on external partners is fostering consolidation among suppliers; for example, SeQuent Scientific received approval in November 2025 for a merger with Viyash Lifesciences, creating a combined entity with half-year revenues of INR 16,462 million to support the growing outsourcing needs of international clients.

Key Market Players

• Zoetis Inc.
• Alivira Animal Health Limited
• Ofichem Group
• Chempro Group
• Siflon Group
• Qilu Animal Health Products Co., Ltd.
• Chemo Holding, S.L
• SUAN FARMA S.A.U
• MENADIONA
• Excel Industries Ltd

Report Scope

In this report, the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Service Type

• In House
• Contract Outsourcing

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Synthesis Type

• Chemical-based API
• Biological API
• HPAPI

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Animal Type

• Production Animals
• Companion Animals

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Therapeutic Category

• Antiparasitic
• Anti-infectives
• NSAIDs
• Others

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market.

Available Customizations:

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service Type (In House, Contract Outsourcing)
  • 5.2.2. By Synthesis Type (Chemical-based API, Biological API, HPAPI)
  • 5.2.3. By Animal Type (Production Animals, Companion Animals)
  • 5.2.4. By Therapeutic Category (Antiparasitic, Anti-infectives, NSAIDs, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service Type
  • 6.2.2. By Synthesis Type
  • 6.2.3. By Animal Type
  • 6.2.4. By Therapeutic Category
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service Type
      • 6.3.1.2.2. By Synthesis Type
      • 6.3.1.2.3. By Animal Type
      • 6.3.1.2.4. By Therapeutic Category
  • 6.3.2. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service Type
      • 6.3.2.2.2. By Synthesis Type
      • 6.3.2.2.3. By Animal Type
      • 6.3.2.2.4. By Therapeutic Category
  • 6.3.3. Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service Type
      • 6.3.3.2.2. By Synthesis Type
      • 6.3.3.2.3. By Animal Type
      • 6.3.3.2.4. By Therapeutic Category

7. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service Type
  • 7.2.2. By Synthesis Type
  • 7.2.3. By Animal Type
  • 7.2.4. By Therapeutic Category
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service Type
      • 7.3.1.2.2. By Synthesis Type
      • 7.3.1.2.3. By Animal Type
      • 7.3.1.2.4. By Therapeutic Category
  • 7.3.2. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service Type
      • 7.3.2.2.2. By Synthesis Type
      • 7.3.2.2.3. By Animal Type
      • 7.3.2.2.4. By Therapeutic Category
  • 7.3.3. United Kingdom Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service Type
      • 7.3.3.2.2. By Synthesis Type
      • 7.3.3.2.3. By Animal Type
      • 7.3.3.2.4. By Therapeutic Category
  • 7.3.4. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service Type
      • 7.3.4.2.2. By Synthesis Type
      • 7.3.4.2.3. By Animal Type
      • 7.3.4.2.4. By Therapeutic Category
  • 7.3.5. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service Type
      • 7.3.5.2.2. By Synthesis Type
      • 7.3.5.2.3. By Animal Type
      • 7.3.5.2.4. By Therapeutic Category

8. Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service Type
  • 8.2.2. By Synthesis Type
  • 8.2.3. By Animal Type
  • 8.2.4. By Therapeutic Category
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service Type
      • 8.3.1.2.2. By Synthesis Type
      • 8.3.1.2.3. By Animal Type
      • 8.3.1.2.4. By Therapeutic Category
  • 8.3.2. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service Type
      • 8.3.2.2.2. By Synthesis Type
      • 8.3.2.2.3. By Animal Type
      • 8.3.2.2.4. By Therapeutic Category
  • 8.3.3. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service Type
      • 8.3.3.2.2. By Synthesis Type
      • 8.3.3.2.3. By Animal Type
      • 8.3.3.2.4. By Therapeutic Category
  • 8.3.4. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service Type
      • 8.3.4.2.2. By Synthesis Type
      • 8.3.4.2.3. By Animal Type
      • 8.3.4.2.4. By Therapeutic Category
  • 8.3.5. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service Type
      • 8.3.5.2.2. By Synthesis Type
      • 8.3.5.2.3. By Animal Type
      • 8.3.5.2.4. By Therapeutic Category

9. Middle East & Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service Type
  • 9.2.2. By Synthesis Type
  • 9.2.3. By Animal Type
  • 9.2.4. By Therapeutic Category
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service Type
      • 9.3.1.2.2. By Synthesis Type
      • 9.3.1.2.3. By Animal Type
      • 9.3.1.2.4. By Therapeutic Category
  • 9.3.2. UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service Type
      • 9.3.2.2.2. By Synthesis Type
      • 9.3.2.2.3. By Animal Type
      • 9.3.2.2.4. By Therapeutic Category
  • 9.3.3. South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service Type
      • 9.3.3.2.2. By Synthesis Type
      • 9.3.3.2.3. By Animal Type
      • 9.3.3.2.4. By Therapeutic Category

10. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service Type
  • 10.2.2. By Synthesis Type
  • 10.2.3. By Animal Type
  • 10.2.4. By Therapeutic Category
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service Type
      • 10.3.1.2.2. By Synthesis Type
      • 10.3.1.2.3. By Animal Type
      • 10.3.1.2.4. By Therapeutic Category
  • 10.3.2. Colombia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service Type
      • 10.3.2.2.2. By Synthesis Type
      • 10.3.2.2.3. By Animal Type
      • 10.3.2.2.4. By Therapeutic Category
  • 10.3.3. Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service Type
      • 10.3.3.2.2. By Synthesis Type
      • 10.3.3.2.3. By Animal Type
      • 10.3.3.2.4. By Therapeutic Category

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Alivira Animal Health Limited
• 15.3. Ofichem Group
• 15.4. Chempro Group
• 15.5. Siflon Group
• 15.6. Qilu Animal Health Products Co., Ltd.
• 15.7. Chemo Holding, S.L
• 15.8. SUAN FARMA S.A.U
• 15.9. MENADIONA
• 15.10. Excel Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer